150 related articles for article (PubMed ID: 35178031)
1. Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations.
Pla Peris B; Arranz Martin A; Ballesteros García A; Sebastián-Valles F; Marazuela Azpiroz M
Front Endocrinol (Lausanne); 2022; 13():802612. PubMed ID: 35178031
[TBL] [Abstract][Full Text] [Related]
2. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
[TBL] [Abstract][Full Text] [Related]
3. S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia.
Thomas K; Germain M; Loch MM
J Investig Med High Impact Case Rep; 2022; 10():23247096221105249. PubMed ID: 35712858
[TBL] [Abstract][Full Text] [Related]
4. A multidisciplinary approach to optimizing care of patients treated with alpelisib.
Rugo HS; Lacouture ME; Goncalves MD; Masharani U; Aapro MS; O'Shaughnessy JA
Breast; 2022 Feb; 61():156-167. PubMed ID: 35016012
[TBL] [Abstract][Full Text] [Related]
5. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
Tankova T; Senkus E; Beloyartseva M; Borštnar S; Catrinoiu D; Frolova M; Hegmane A; Janež A; Krnić M; Lengyel Z; Marcou Y; Mazilu L; Mrinakova B; Percik R; Petrakova K; Rubovszky G; Tokar M; Vrdoljak E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406370
[TBL] [Abstract][Full Text] [Related]
6. DIABETIC KETOACIDOSIS ASSOCIATED WITH ALPELISIB TREATMENT OF METASTATIC BREAST CANCER.
Farah SJ; Masri N; Ghanem H; Azar M
AACE Clin Case Rep; 2020; 6(6):e349-e351. PubMed ID: 33244501
[TBL] [Abstract][Full Text] [Related]
7. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
Blow T; Hyde PN; Falcone JN; Neinstein A; Vasan N; Chitkara R; Hurd MA; Sardesai S; Lustberg MB; Flory JH; Volek JS; Goncalves MD
Integr Cancer Ther; 2021; 20():15347354211032283. PubMed ID: 34259084
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib-induced hyperglycemia in older patients with breast Cancer: Qualitative findings.
Cook K; Almodallal Y; Martin N; Jatoi A
J Geriatr Oncol; 2021 Sep; 12(7):1114-1117. PubMed ID: 33752998
[TBL] [Abstract][Full Text] [Related]
9. Periorbital edema associated with alpelisib.
Dao EA; George SJ; Heberton MM; Pacha O; Kovitz CA; Patel AB; Phillips RM
Cancer Treat Res Commun; 2022; 32():100596. PubMed ID: 35834907
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamic of Alpelisib.
Royer B; Kaderbhaï CG; Schmitt A
Clin Pharmacokinet; 2023 Jan; 62(1):45-53. PubMed ID: 36633813
[TBL] [Abstract][Full Text] [Related]
11. ALPELISIB - INDUCED HYPERGLYCEMIA.
Ekanayake PS; Gerwer J; Mccowen K
Acta Endocrinol (Buchar); 2022; 18(1):115-117. PubMed ID: 35975254
[TBL] [Abstract][Full Text] [Related]
12. Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer - A Real-Life Experience.
Percik R; Oedegaard Smith C; Leibovici A; Shai A
Biologics; 2023; 17():61-67. PubMed ID: 37163178
[TBL] [Abstract][Full Text] [Related]
13. Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia.
Goncalves MD; Farooki A
Integr Cancer Ther; 2022; 21():15347354211073163. PubMed ID: 35075945
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
Sahakian N; Cattieuw L; Ramillon-Cury C; Corroller AB; Silvestre-Aillaud P; Béliard S; Valéro R
Clin Diabetes Endocrinol; 2021 Jul; 7(1):17. PubMed ID: 34281618
[TBL] [Abstract][Full Text] [Related]
15. Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Carrillo M; Rodriguez RM; Walsh CL; Mcgarvey M
AACE Clin Case Rep; 2021; 7(2):127-131. PubMed ID: 34095470
[TBL] [Abstract][Full Text] [Related]
16. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
17. Diabetic Ketoacidosis With the Use of Alpelisib in a Patient With Metastatic Breast Cancer Without Diabetes.
Polisetty L; Teresa Selvin S; Tan JW
JCEM Case Rep; 2024 Apr; 2(4):luae023. PubMed ID: 38524964
[TBL] [Abstract][Full Text] [Related]
18. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Abufaied M; Jumbo U; Alqalalwah A; Hamad MK
Cureus; 2021 Nov; 13(11):e19441. PubMed ID: 34909343
[TBL] [Abstract][Full Text] [Related]
19. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
20. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
